Skip to main content

Articles

Page 17 of 19

  1. Protease inhibitors such as ritonavir can cause nausea and vomiting which is the most common reason for discontinuation. Rats react to nauseous and emetic stimuli by increasing their oral intake of non-nutriti...

    Authors: Chun-Su Yuan, Chong-Zhi Wang, Sangeeta R Mehendale, Han H Aung, Adela Foo and Robert J Israel
    Citation: AIDS Research and Therapy 2009 6:19
  2. Roche's protease inhibitor nelfinavir mesylate (Viracept®) produced between March 2007-June 2007 was found to contain elevated levels of ethyl methanesulfonate (EMS), a known mutagen (alkylator) – leading to a gl...

    Authors: Anton Pozniak, Lutz Müller, Miklos Salgo, Judith K Jones, Peter Larson and David Tweats
    Citation: AIDS Research and Therapy 2009 6:18
  3. Many HIV-infected patients only access health care once they have developed advanced symptomatic disease resulting from AIDS Defining Conditions (ADCs). We carried out a study to establish the effect of ADCs o...

    Authors: Brian K Kigozi, Samwel Sumba, Peter Mudyope, Betty Namuddu, Joan Kalyango, Charles Karamagi, Mathew Odere, Elly Katabira, Peter Mugyenyi and Francis Ssali
    Citation: AIDS Research and Therapy 2009 6:17
  4. To immunophenotype CD4+ and CD8+ T cell sub-populations in HIV-associated immune reconstitution inflammatory syndrome (IRIS).

    Authors: David M Murdoch, Melinda S Suchard, Willem DF Venter, Patrick Mhlangu, Janet S Ottinger, Charles Feldman, Annelies Van Rie, Deborah K Glencross, Wendy S Stevens and Kent J Weinhold
    Citation: AIDS Research and Therapy 2009 6:16
  5. The latency of HIV-1 in resting CD4+ T-lymphocytes constitutes a major obstacle for the eradication of virus in patients on antiretroviral therapy (ART). As yet, no approach to reduce this viral reservoir has pro...

    Authors: Annica Lindkvist, Arvid Edén, Melissa M Norström, Veronica D Gonzalez, Staffan Nilsson, Bo Svennerholm, Annika C Karlsson, Johan K Sandberg, Anders Sönnerborg and Magnus Gisslén
    Citation: AIDS Research and Therapy 2009 6:15
  6. HIV-1 integrase (IN) is an attractive target for the development of drugs to treat AIDS, and inhibitors of this viral enzyme are already in the clinic. Nevertheless, there is a continuing need to devise new ap...

    Authors: Mark D Andrake, Joseph Ramcharan, George Merkel, Xue Zhi Zhao, Terrence R Burke Jr and Anna Marie Skalka
    Citation: AIDS Research and Therapy 2009 6:14
  7. Antiretrovirals used to treat HIV-infected patients have the potential to adversely affect serum lipid profiles and increase the risk of cardiovascular disease which is an emerging concern among HIV-infected p...

    Authors: Anuradha Ganesan, Lorie Benning, Elizabeth T Golub, Mark Riddle, Nancy Crum-Cianflone, Sybil Tasker, Lisa Jacobson and Stephen J Gange
    Citation: AIDS Research and Therapy 2009 6:13
  8. Access to antiretroviral therapy (ART) is increasing in resource-limited settings (RLS) and can successfully reduce HIV-related morbidity and mortality. However, virologic failure and development of viral drug...

    Authors: Kim Steegen, Stanley Luchters, Kenny Dauwe, Jacqueline Reynaerts, Kishor Mandaliya, Walter Jaoko, Jean Plum, Marleen Temmerman and Chris Verhofstede
    Citation: AIDS Research and Therapy 2009 6:12
  9. Non-invasive surrogate measures which are valid and responsive to change are needed to study cardiovascular risks in HIV. We compared the construct validity of two noninvasive arterial measures: carotid intima...

    Authors: Adefowope Odueyungbo, Marek Smieja, Lehana Thabane, Fiona Smaill, Kevin Gough, John Gill, Todd Anderson, Dawn Elston, Sandy Smith, Joseph Beyene and Eva Lonn
    Citation: AIDS Research and Therapy 2009 6:11
  10. Two HIV-1 infected patients developed signs and symptoms consistent with adrenal suppression after being exposed to intra-articular triamcinolone acetate while also receiving ritonavir as part of their highly ...

    Authors: Kathryn Dort, Shetal Padia, Brian Wispelwey and Christopher C Moore
    Citation: AIDS Research and Therapy 2009 6:10
  11. Successful treatment of HIV-positive patients is fundamental to controlling the progression to AIDS. Causes of treatment failure are either related to drug resistance and/or insufficient drug levels in the blo...

    Authors: IRichard Thompson, Penelope Bidgood, Andrea Petróczi, James CW Denholm-Price and Mark D Fielder
    Citation: AIDS Research and Therapy 2009 6:9
  12. Fat abnormalities are common among HIV-infected persons, but few studies have compared regional body fat distribution, including visceral fat, in HIV-infected and HIV-uninfected persons and their subsequent tr...

    Authors: Todd T Brown, Xiaoqiang Xu, Majnu John, Jaya Singh, Lawrence A Kingsley, Frank J Palella, Mallory D Witt, Joseph B Margolick and Adrian S Dobs
    Citation: AIDS Research and Therapy 2009 6:8
  13. Human Immunodeficiency Virus (HIV) has an estimated prevalence of 0.9% in India (5.2 million). Anti-retroviral drugs (ARV) are the treatments of choice and non-adherence is an important factor in treatment failur...

    Authors: Mary B Cauldbeck, Catherine O'Connor, Mortimer B O'Connor, Jean A Saunders, Bhimasena Rao, V G Mallesh, Nagendrappa Kotehalappa Praveen Kumar, Gurushanthappa Mamtha, Claire McGoldrick, Robert BS Laing and Kadappa Shivappa Satish
    Citation: AIDS Research and Therapy 2009 6:7
  14. Prognosis for patients with the human immunodeficiency virus (HIV) has improved with the introduction of highly active antiretroviral therapy (HAART). Evidence over recent years suggests that the incidence of ...

    Authors: Julián Olalla, Daniel Salas, Javier de la Torre, Alfonso del Arco, José Luis Prada, Francisco Martos, Emilio Perea-Milla and Javier García-Alegría
    Citation: AIDS Research and Therapy 2009 6:6
  15. Most in vitro assays of drug potency may not adequately predict the performance in vivo. Methods to assess the persistence of antiviral activity of deoxynucleoside analogs, which require intracellular activati...

    Authors: Elijah Paintsil, Susan P Grill, Ginger E Dutschman and Yung-Chi Cheng
    Citation: AIDS Research and Therapy 2009 6:5
  16. About 20–30% of persons with HIV infection, especially those living in countries with limited resources, experience an immune reconstitution inflammatory syndrome (IRIS) after starting antiretroviral treatment...

    Authors: Anali Conesa-Botella, Chantal Mathieu, Robert Colebunders, Rodrigo Moreno-Reyes, Evelyne van Etten, Lut Lynen and Luc Kestens
    Citation: AIDS Research and Therapy 2009 6:4
  17. Traditional first line regimens containing a non-nucleoside reverse transcriptase inhibitor or protease inhibitor may not be suitable for a subset of antiretroviral-naïve patients such as those with certain co...

    Authors: Princy N Kumar, Patricia Salvato, Anthony LaMarca, Edwin DeJesus, Parul Patel, Daniel McClernon, Allison Florance and Mark S Shaefer
    Citation: AIDS Research and Therapy 2009 6:3
  18. The selection of agents for any treatment regimen is in part influenced by physician and patient attitudes. This study investigated attitudinal motivators and barriers to the use of self-injectable antiretrovi...

    Authors: Robert Horne, Colin Kovacs, Christine Katlama, Bonaventura Clotet, Carmina R Fumaz, Michael Youle, Ranjababu Kulasegaram, Martin Fisher, Calvin Cohen, Jihad Slim, Peter Shalit, Vanessa Cooper and Christos Tsoukas
    Citation: AIDS Research and Therapy 2009 6:2
  19. HIV-infected individuals are at increased risk for acute and chronic airway disease even though there is no evidence that the virus can infect the lung epithelium. Although HIV-related proteins including gp120...

    Authors: Coy Lassiter, Xian Fan, Pratibha C Joshi, Barbara A Jacob, Roy L Sutliff, Dean P Jones, Michael Koval and David M Guidot
    Citation: AIDS Research and Therapy 2009 6:1
  20. CD4 count is a standard measure of immunodeficiency in adults infected with HIV to initiate and monitor highly active antiretroviral therapy; however, it may not be feasible in resource poor countries. There i...

    Authors: Deresse Daka and Eskindir Loha
    Citation: AIDS Research and Therapy 2008 5:26
  21. Allopathic practitioners in India are outnumbered by practitioners of traditional Indian medicine and homeopathy (TIMH), which is used by up to two-thirds of its population to help meet primary health care nee...

    Authors: M Fritts, CC Crawford, D Quibell, A Gupta, WB Jonas, I Coulter and SA Andrade
    Citation: AIDS Research and Therapy 2008 5:25
  22. To evaluate the feasibility of a large immediate versus deferred antiretroviral therapy (ART) study in children.

    Authors: Jintanat Ananworanich, Pope Kosalaraksa, Umaporn Siangphoe, Chulapan Engchanil, Chitsanu Pancharoen, Pagakrong Lumbiganon, Jintana Intasan, Wichitra Apateerapong, Theshinee Chuenyam, Sasiwimol Ubolyam, Torsak Bunupuradah, Joep Lange, David A Cooper and Praphan Phanuphak
    Citation: AIDS Research and Therapy 2008 5:24
  23. A proportion of individuals who start antiretroviral therapy (ART) fail to achieve adequate CD4 cell reconstitution despite sustained viral suppression. We determined the frequency and clinical significance of...

    Authors: Damalie Nakanjako, Agnes Kiragga, Fowzia Ibrahim, Barbara Castelnuovo, Moses R Kamya and Philippa J Easterbrook
    Citation: AIDS Research and Therapy 2008 5:23
  24. T-cell mediated immunity likely plays an important role in controlling HIV-1 infection and progression to AIDS. Several candidate vaccines against HIV-1 aim at stimulating cellular immune responses, either alo...

    Authors: Sarah Kutscher, Claudia J Dembek, Simone Allgayer, Silvia Heltai, Birgit Stadlbauer, Priscilla Biswas, Silvia Nozza, Giuseppe Tambussi, Johannes R Bogner, Hans J Stellbrink, Frank D Goebel, Paolo Lusso, Marco Tinelli, Guido Poli, Volker Erfle, Heike Pohla…
    Citation: AIDS Research and Therapy 2008 5:22
  25. The tablet formulation of ritonavir-boosted lopinavir (LPV/r; Kaletra®) has many advantages over the soft gel capsule (SGC) formulation, including lower pill count, no refrigeration requirement, and no dietary re...

    Authors: Shannon Schrader, Susan K Chuck, Laurie W Rahn, Paras Parekh and Katherine G Emrich
    Citation: AIDS Research and Therapy 2008 5:21
  26. Newer antiretroviral (ARV) agents have improved pharmacokinetics, potency, and tolerability and have enabled the design of regimens with improved virologic outcomes. Successful antiretroviral therapy is depend...

    Authors: William C Mathews, Eva Barker, Erica Winter, Craig Ballard, Bradford Colwell and Susanne May
    Citation: AIDS Research and Therapy 2008 5:20
  27. Recently revised statistics show the number of individuals living with HIV at over 33 million worldwide, with 68% being in sub-Saharan Africa. Current HIV prevention methods, such as condom use, monogamy and a...

    Authors: Gita Ramjee, Gustavo F Doncel, Sanjay Mehendale, Elizabeth E Tolley and Kim Dickson
    Citation: AIDS Research and Therapy 2008 5:19
  28. Current diagnostic assays for HIV-1 do not always test for the presence of HIV-2 in the United States. We present the case of a patient from Cape Verde, who was admitted to our hospital with rapidly deteriorat...

    Authors: Philip A Chan, Sarah E Wakeman, Timothy Flanigan, Susan Cu-Uvin, Erna Kojic and Rami Kantor
    Citation: AIDS Research and Therapy 2008 5:18
  29. Prevention of mother-to-child transmission of HIV (PMTCT) is a major public health challenge in Zimbabwe.

    Authors: Avinash K Shetty, Caroline Marangwanda, Lynda Stranix-Chibanda, Winfreda Chandisarewa, Elizabeth Chirapa, Agnes Mahomva, Anna Miller, Micah Simoyi and Yvonne Maldonado
    Citation: AIDS Research and Therapy 2008 5:17
  30. Access to antiretroviral drugs for HIV-1 infection has increased in sub-Saharan Africa (SSA) during the past few years. Mutations in the HIV-1 genome are often associated with treatment failure as indicated by...

    Authors: Balthazar M Nyombi, Carol Holm-Hansen, Knut I Kristiansen, Gunnar Bjune and Fredrik Müller
    Citation: AIDS Research and Therapy 2008 5:13
  31. Human T-cell leukemia virus type-1 (HTLV-1) induces adult T-cell leukemia/lymphoma (ATL/L), a fatal lymphoproliferative disorder, and HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP), a chro...

    Authors: Emmanuel Agbottah, Wen-I Yeh, Reem Berro, Zachary Klase, Caitlin Pedati, Kyleen Kehn-Hall, Weilin Wu and Fatah Kashanchi
    Citation: AIDS Research and Therapy 2008 5:12
  32. Human immunodeficiency virus type 1 (HIV-1)-based gene delivery systems are popular due to their superior efficiency of transduction of primary cells. However, these systems cannot be readily used for delivery...

    Authors: Narasimhachar Srinivasakumar
    Citation: AIDS Research and Therapy 2008 5:11
  33. Terpenoid derivatives originating from many plants species, are interesting compounds with numerous biological effects, such as anti-HIV-1 activity. The zinc tetra-ascorbo-camphorate complex (or "C14"), a new ...

    Authors: Héla Saïdi, Mohammad-Ali Jenabian, Bernard Gombert, Charlotte Charpentier, Aurèle Mannarini and Laurent Bélec
    Citation: AIDS Research and Therapy 2008 5:10
  34. Immune restoration disease (IRD) is an adverse consequence of antiretroviral therapy, where the restored pathogen-specific response causes immunopathology. Mycobacteria are the pathogens that most frequently p...

    Authors: Andrew Lim, Lloyd D'Orsogna, Patricia Price and Martyn A French
    Citation: AIDS Research and Therapy 2008 5:9
  35. Human immunodeficiency virus type 1 (HIV-1) infection and the consequent acquired immunodeficiency syndrome (AIDS) has protean manifestations, including muscle wasting and cardiomyopathy, which contribute to i...

    Authors: Jeffrey S Otis, Yaroslav I Ashikhmin, Lou AnnS Brown and David M Guidot
    Citation: AIDS Research and Therapy 2008 5:8
  36. According to Vietnamese policy, HIV-infected women should have access at least to HIV testing and Nevirapine prophylaxis, or where available, to adequate counselling, HIV infection staging, ARV prophylaxis, an...

    Authors: Thu Anh Nguyen, Pauline Oosterhoff, Yen Pham Ngoc, Pamela Wright and Anita Hardon
    Citation: AIDS Research and Therapy 2008 5:7
  37. Although Venezuela has a National Human Immunodeficiency Virus (HIV) Program offering free diagnosis and treatment, 41% of patients present for diagnosis at a later disease-stage, indicating that access to car...

    Authors: Maeva A Bonjour, Morelba Montagne, Martha Zambrano, Gloria Molina, Catherine Lippuner, Francis G Wadskier, Milvida Castrillo, Renzo N Incani and Adriana Tami
    Citation: AIDS Research and Therapy 2008 5:6
  38. Once-daily (QD) ritonavir 100 mg-boosted fosamprenavir 1400 mg (FPV/r100) or atazanavir 300 mg (ATV/r100), plus tenofovir/emtricitabine (TDF/FTC) 300 mg/200 mg, have not been compared as initial antiretroviral...

    Authors: Kimberly Y Smith, Winkler G Weinberg, Edwin DeJesus, Margaret A Fischl, Qiming Liao, Lisa L Ross, Gary E Pakes, Keith A Pappa and CTracey Lancaster
    Citation: AIDS Research and Therapy 2008 5:5
  39. In a routine service delivery setting in Uganda, we assessed the ability of the WHO clinical stage to accurately identify HIV-infected patients in whom antiretroviral therapy should be started.

    Authors: Shabbar Jaffar, Josephine Birungi, Heiner Grosskurth, Barbara Amuron, Geoffrey Namara, Christine Nabiryo and Alex Coutinho
    Citation: AIDS Research and Therapy 2008 5:4
  40. Kaposi Sarcoma (KS) is a multifocal angioproliferative neoplasm characterized by inflammation, oedema, neoangiogenesis and spindle cell proliferation. The pathogenesis of human immunodeficiency virus (HIV)-ass...

    Authors: L Feller, JN Masipa, NH Wood, EJ Raubenheimer and J Lemmer
    Citation: AIDS Research and Therapy 2008 5:2
  41. Gut immune components are severely compromised among persons with AIDS, which allows increased translocation of bacterial lipopolysaccharides (LPS) into the systemic circulation. These microbial LPS are report...

    Authors: Esaki Muthu Shankar, Ramachandran Vignesh, Kailapuri G Murugavel, Pachamuthu Balakrishnan, Ramalingam Sekar, Charmaine AC Lloyd, Suniti Solomon and Nagalingeswaran Kumarasamy
    Citation: AIDS Research and Therapy 2007 4:29
  42. As HIV treatment is scaled-up in resource-poor settings, the timely identification of persons with HIV infection remains an important challenge. Most people with HIV are unaware of their status, and those who ...

    Authors: Louise C Ivers, Kenneth A Freedberg and Joia S Mukherjee
    Citation: AIDS Research and Therapy 2007 4:28
  43. The objective of this study was to examine missed opportunities for participation in a prevention of mother-to-child transmission (PMTCT) programme in three sites in South Africa. A rapid anthropological asses...

    Authors: Lungiswa L Nkonki, Tanya M Doherty, Zelee Hill, Mickey Chopra, Nikki Schaay and Carl Kendall
    Citation: AIDS Research and Therapy 2007 4:27
  44. Non-nucleoside reverse transcriptase inhibitor (NNRTI) with stavudine and lamivudine is widely used as the first-line antiretroviral therapy (ART) in resource-limited settings. Lipodystrophy is common and opti...

    Authors: Somnuek Sungkanuparph, Sasisopin Kiertiburanakul, Anucha Apisarnthanarak, Kumthorn Malathum, Siriorn Watcharananan and Boonmee Sathapatayavongs
    Citation: AIDS Research and Therapy 2007 4:26
  45. Epidemiologic studies indicate that bacterial vaginosis (BV), a common alteration of lower genital tract flora in women, is associated with increased susceptibility to HIV infection. Other recent studies show ...

    Authors: Gregory T Spear, Elizabeth St John and MReza Zariffard
    Citation: AIDS Research and Therapy 2007 4:25